NCT05358548 is a Phase 2 clinical trial of Paclitaxel in Head and Neck Cancer, sponsored by Rutgers, The State University of New Jersey.

Who is sponsoring NCT05358548?

NCT05358548 is sponsored by Rutgers, The State University of New Jersey.

What drugs are being tested in NCT05358548?

Interventions in NCT05358548: Paclitaxel, Pemetrexed, 5Fluorouracil, Carboplatin, Pembrolizumab.

What condition does NCT05358548 study?

NCT05358548 studies Head and Neck Cancer, Lung Cancer.

Is NCT05358548 still recruiting?

NCT05358548 is currently recruiting now. Last updated 10 April 2024.

Last reviewed 2024-04-10 · How we verify

NCT05358548

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATATcH Alternating Treatment Plans for Advanced Cancer

Recruiting now Phase 2 Last updated 10 April 2024

What this trial tests

Phase 2 trial testing Paclitaxel in Head and Neck Cancer in 150 participants. Currently enrolling.

Timeline

28 April 2022

Primary endpoint
1 May 2025

1 December 2025

Quick facts

Lead sponsor	Rutgers, The State University of New Jersey
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	28 April 2022
Primary completion	1 May 2025
Estimated completion	1 December 2025
Sites	11 locations across United States

Drugs / interventions tested

Paclitaxel — full drug profile →
Pemetrexed — full drug profile →
5Fluorouracil
Carboplatin
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

Rutgers, The State University of New Jersey

Who can join

18 and older, any sex, with Head and Neck Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Harnessing nucleotide metabolism and immunity in cancer: a tumour microenvironment perspective.
Suleiman H, Emerson A, Wilson PM, Mulligan KA, et al · · 2025 · cited 7× · PMID 39308084 · DOI 10.1111/febs.17278

Verify or expand the search:

Other trials of Paclitaxel

Trials testing the same drug.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
NCT07465757 — A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) · Phase 2 · not yet recruiting

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Rutgers, The State University of New Jersey trials

Trials by the same sponsor.

NCT07243886 — Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD) · NA · not yet recruiting
NCT06955130 — Lactate and Glycerol Contribution to Gluconeogenesis · NA · not yet recruiting
NCT06822010 — SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma · Phase 2 · not yet recruiting
NCT07525011 — Comparative Study of Denture Fabrication Techniques · NA · not yet recruiting
NCT06834204 — Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05358548 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rutgers, The State University of New Jersey
Last refreshed: 10 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05358548.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing